Skip to main content
ControlRad, Inc.Portfolio

ControlRad adds five people to leadership team

By December 17, 2019March 25th, 2021No Comments

ControlRad announced today that it made several additions to its leadership team, naming a new chief financial officer, VP of U.S. operations, VP of marketing and two new VPs of sales.

The Atlanta-based company named Peter Pizzo as its new CFO. Pizzo has more than 25 years of experience in senior financial roles, having previously served as CFO at Cartiva before it was purchased by Wright Medical (NSDQ:WMGI).

Amy Lazarus was tabbed as the new VP of U.S. operations, having previously held several roles at General Electric (NYSE:GE), including general manager of the interventional service business. The company also named former Zimmer Biomet (NYSE:ZBH) spine division general manager Joe Ross as its new VP of marketing.

ControlRad also selected Sean Finnerty and Timothy Hein as area VP of sales in the east and west, respectively. Finnerty previously served as national sales manager at Cartiva, while Hein was VP of sales for Paradigm Spine before it was acquired by RTI Surgical (NSDQ:RTIX).

Pizzo and Finnerty are the second and third former Cartiva employees to join ControlRad in recent months after the company added former Cartiva co-founder & CEO Tim Patrick to its board in October after collecting $15 million in a Series B funding round.

“2019 was a significant year for ControlRad, with FDA clearance and initial installations of our first product,” ControlRad CEO Guillaume Bailliard said in a news release. “The wealth of experience that Peter, Amy, Joe, Sean and Tim bring in introducing new products to the market will be invaluable as we ramp up commercialization for ControlRad Trace in 2020.”

The ControlRad Trace is an FDA-approved device for reducing radiation in fluoroscopically guided procedures. The system uses a proprietary semi-transparent filter, along with its tablet and image processing technology for retrofitting on existing C-arms in radiation reduction. It’s designed to allow medical professionals to draw a region of interest on the ControlRad tablet, which optimizes image quality in that area while reducing radiation in the periphery.

The Trace system is the first FDA-cleared technology that can be integrated into existing mobile C-arms to reduce the ionizing radiation that can occur in fluoroscopically guided procedures. The Trace technology reduces radiation exposure by up to 89%, according to previous clinical trials.

Rapha Capital Management, LLC is providing this website for informational purposes only. Nothing on this website is intended to constitute, or should be deemed to be, financial advisory, legal, tax, accounting or other professional advice to you or any other party; be an opinion of the appropriateness or suitability of any investment; or constitute an offer to sell or solicitation of an offer to buy any security or investment. This website and its content (collectively, “Content”) is intended for general informational purposes only and should not be acted upon without first obtaining financial advisory, legal, tax, accounting or other professional advice from your consultant or other professional with respect to your own personal investment objectives, financial circumstances and needs. Nothing on the Site shall be considered a recommendation or solicitation to buy or an offer to sell a security to any person in any jurisdiction where such offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction. Any investment decisions you may make on the basis of any information found on this web site is your sole responsibility. Prior to making any investment or hiring any investment manager you should consult with a professional financial advisor, legal and tax advisor to assist in due diligence as may be appropriate and determining the appropriateness of the risk associated with a particular investment. In no event shall Rapha Capital Management, LLC be responsible or liable for the correctness of any such material or for any damage or lost opportunities resulting from use of these data.